«Ульяновский медико-биологический журнал»

CLINICAL MEDICINE

Download  article

DOI 10.34014/2227-1848-2021-2-83-96

CLINICAL CHARACTERISTICS, PROGNOSIS AND TREATMENT OF ANDROGEN-RECEPTOR-POSITIVE TRIPLE-NEGATIVE BREAST CANCER

I.S. Panchenko1, V.V. Rodionov2, S.V. Panchenko1, M.G. Sharafutdinov1

1 Ulyanovsk Syate University, Ulyanovsk, Russia;

2 National Medical Research Center for Obstetrics, Gynecology and Perinatology named after V.I. Kulakov, Ministry of Health of the Russian Federation, Moscow, Russia

 

This literature review focuses on the prognostic, clinical, and therapeutic characteristics of androgen receptor-positive triple-negative breast cancer.

Breast cancer (BC) is the most common malignant tumor among the female population. It accounts for about 21 % of all malignant neoplasms in Russia. The most unfavorable BC subtype is triple negative breast cancer (TNBC). TNBC is a subgroup of malignant breast tumors characterized by an aggressive progress and poor prognosis. It mostly affetcs young women. Despite the high sensitivity to neoadjuvant polychemotherapy, locoregional recurrence rate for TNBC is rarther high. Survival rate for patinets with TNBC is lower compared to patinets with other BC subtypes. Due to the widespread introduction of molecular genetic research methods into the algorithms for BC diagnosis, we can claim that TNBC is a heterogeneous group of tumors with different prognosis, clinical characteristics and response to therapy. Currently, drug therapy for TNBC is based solely on systemic chemotherapy. National treatment standards do not suggest any methods to treat this type of tumor. However, according to recent studies, antiandrogenic drugs can be successfully used in the TNBC therapy. The study of androgen receptor-positive triple-negative breast cancer seems promising for two reasons. The first reason is the availability of IHC diagnostics in most oncological centers in Russia. The second reason is the availability of relatively inexpensive endocrine therapy.

Keywords: breast cancer, triple negative breast cancer, androgen receptor positive triple negative breast cancer, androgen receptors, androgen receptor expression, antiandrogen therapy.

Conflict of interest. The authors declare no conflict of interest.

 

References

  1. Chissov V.I., Dar'yalova S.L. Onkologiya: uchebnik s kompakt-diskom [Oncology: textbook with CD]. Moscow: GEOTAR-Media; 2009. 560 (in Russian).

  2. GLOBOCAN 2020. Available at: https://acsjournals.onlinelibrary.wiley.com/doi/full/10.3322/ caac.21660 (accessed: April 27, 2021).

  3. Kaprin A.D., Starinskiy V.V., Shakhzadova A.O. Zlokachestvennye novoobrazovaniya v Rossii v 2019 godu [Malignant neoplasms in Russia in 2019]. Moscow: MNIOI im. P.A. Gertsena – filial FGBU «NMITs radiologii» Minzdrava Rossii; 2020. 252 (in Russian).

  4. Pankaj Kumar, Rupali Aggarwal. An overview of triple-negative breast cancer. Arch. Gynecol. Obstet. 2016; 293 (2): 247–269. Available at: https://pubmed.ncbi.nlm.nih.gov/26341644/ (accessed: April 16, 2021). DOI: 10.1007/s00404-015-3859-y.

  5. Lubna N. Chaudhary. Early stage triple negative breast cancer: Management and future directions. Semin. Oncol. 2020; 47 (4): 201–208. Available at: https://pubmed.ncbi.nlm.nih.gov/32507668/ (accessed: April 16, 2021). DOI: 10.1053/j.seminoncol.2020.05.006.

  6. Cornelia Liedtke, Chafika Mazouni, Kenneth R. Hess, Fabrice André, Attila Tordai, Jaime A. Mejia, W. Fraser Symmans, Ana M. Gonzalez-Angulo, Bryan Hennessy, Marjorie Green, Massimo Cristofanilli, Gabriel N. Hortobagyi, Lajos Pusztai. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J. Clin. Oncol. 2008; 26 (8): 1275–1281. Available at: https://pubmed.ncbi.nlm.nih.gov/18250347/ (accessed: April 16, 2021). DOI: 10.1200/JCO.2007.14.4147.

  7. Xiaoxian Li, Jing Yang, Limin Peng, Aysegul A. Sahin, Lei Huo, Kevin C. Ward, Ruth O'Regan, Mylin A. Torres, Jane L. Meisel. Triple-negative breast cancer has worse overall survival and cause-specific survival than non-triple-negative breast cancer. Breast Cancer Res. Treat. 2017; 161 (2): 279–287. Available at: https://pubmed.ncbi.nlm.nih.gov/27888421/ (accessed: April 16, 2021). DOI: 10.1007/s10549-016-4059-6.

  8. Marissa C. van Maaren, Linda de Munck, Luc J.A. Strobbe, Gabe S. Sonke, Pieter J. Westenend, Marjolein L. Smidt, Philip M.P. Poortmans, Sabine Siesling. Ten-year recurrence rates for breast cancer subtypes in the Netherlands: A large population-based study. Int. J. Cancer. 2019; 144 (2): 263–272. Available at: https://pubmed.ncbi.nlm.nih.gov/30368776/ (accessed: April 17, 2021). DOI: 10.1002/ijc.31914.

  9. Zuzana Sporikova, Vladimira Koudelakova, Radek Trojanec, Marian Hajduch. Genetic Markers in Triple-Negative Breast Cancer. Clin. Breast Cancer. 2018; 18 (5): e841–e850. Available at: https://pubmed.ncbi.nlm.nih.gov/30146351/ (accessed: April 16, 2021). DOI: 10.1016/j.clbc.2018.07.023.

  10. Perou C.M., Sørlie T., Eisen M.B., van de Rijn M., Jeffrey S.S., Rees C.A., Pollack J.R., Ross D.T., Johnsen H., Akslen L.A., Fluge O., Pergamenschikov A., Williams C., Zhu S.X., Lønning P.E., Børresen-Dale A.L., Brown P.O., Botstein D. Molecular portraits of human breast tumours. Nature. 2000; 406 (6797): 747–752. Available at: https://pubmed.ncbi.nlm.nih.gov/10963602/ (accessed: April 17, 2021). DOI: 10.1038/35021093.

  11. Aleix Prat, Joel S. Parker, Olga Karginova, Cheng Fan, Chad Livasy, Jason I. Herschkowitz, Xiaping He, Charles M. Perou. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res. 2010; 12 (5): R68. Available at: https://pubmed.ncbi.nlm.nih.gov/ 20813035/ (accessed: April 17, 2021). DOI: 10.1186/bcr2635.

  12. Farmer Pierre, Bonnefoi Herve, Becette Veronique, Tubiana-Hulin Michele, Fumoleau Pierre, Larsimont Denis, Macgrogan Gaetan, Bergh Jonas, Cameron David, Goldstein Darlene, Duss Stephan, Nicoulaz Anne-Laure, Brisken Cathrin, Fiche Maryse, Delorenzi Mauro, Iggo Richard. Identification of molecular apocrine breast tumours by microarray analysis. Oncogene. 2005; 24 (29): 4660–4671. Available at: https://pubmed.ncbi.nlm.nih.gov/15897907/ (accessed: April 17, 2021). DOI: 10.1038/sj.onc.1208561.

  13. Fitzal F., Filipits M., Fesl C., Rudas M., Greil R., Balic M., Moinfar F., Herz W., Dubsky P., Bartsch R., Ferree S., Schaper C., Gnant M. PAM-50 predicts local recurrence after breast cancer surgery in postmenopausal patients with ER+/HER2- disease: results from 1204 patients in the randomized ABCSG-8 trial. Br. J. Surg. 2021; 108 (3): 308–314. Available at: https://pubmed.ncbi.nlm.nih.gov/33608712/ (accessed: April 17, 2021). DOI: 10.1093/bjs/znaa089.

  14. Brian D. Lehmann, Joshua A. Bauer, Xi Chen, Melinda E. Sanders, A. Bapsi Chakravarthy, Yu Shyr, Jennifer A. Pietenpol. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J. Clin. Invest. 2011; 121 (7): 2750–2767. Available at: https://pubmed.ncbi.nlm.nih.gov/21633166/ (accessed: April 18, 2021). DOI: 10.1172/JCI45014.

  15. Li Yin, Jiang-Jie Duan, Xiu-Wu Bian, Shi-Cang Yu. Triple-negative breast cancer molecular subtyping and treatment progress. Breast Cancer Res. 2020; 22 (1): 61. Available at: https://pubmed.ncbi.nlm.nih.gov/32517735/ (accessed: April 17, 2021). DOI: 10.1186/s13058-020-01296-5.

  16. Matthew D. Burstein, Anna Tsimelzon, Graham M. Poage, Kyle R. Covington, Alejandro Contreras, Suzanne A.W. Fuqua, Michelle I. Savage, C. Kent Osborne , Susan G. Hilsenbeck, Jenny C. Chang, Gordon B. Mills, Ching C. Lau, Powel H. Brown. Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer. Clin. Cancer Res. 2015; 21 (7): 1688–1698. Available at: https://pubmed.ncbi.nlm.nih.gov/25208879/ (accessed: April 18, 2021). DOI: 10.1158/1078-0432.CCR-14-0432.

  17. Yi-Rong Liu, Yi-Zhou Jiang, Xiao-En Xu, Ke-Da Yu, Xi Jin, Xin Hu, Wen-Jia Zuo, Shuang Hao, Jiong Wu, Guang-Yu Liu, Gen-Hong Di, Da-Qiang Li, Xiang-Huo He, Wei-Guo Hu, Zhi-Ming Shao. Comprehensive transcriptome analysis identifies novel molecular subtypes and subtype-specific RNAs of triple-negative breast cancer. Breast Cancer Res. 2016; 18 (1): 33. Available at: https://pubmed.ncbi.nlm.nih.gov/26975198/ (accessed: April 17, 2021). DOI: 10.1186/s13058-016-0690-8.

  18. Clasina M. Venema, Rico D. Bense, Tessa G. Steenbruggen, Hilde H. Nienhuis, Si-Qi Qiu, Michel van Kruchten, Myles Brown, Rulla M. Tamimi, Geke A.P. Hospers, Carolina P. Schröder, Rudolf S.N. Fehrmann, Elisabeth G.E. de Vries. Consideration of breast cancer subtype in targeting the androgen receptor. Pharmacol. Ther. 2019; 200: 135–147 Available at: https://pubmed.ncbi.nlm.nih.gov/31077689/ (accessed: April 18, 2021). DOI: 10.1016/j.pharmthera.2019.05.005.

  19. Debashis Sarker, Alison H.M. Reid, Timothy A. Yap, Johann S. de Bono. Targeting the PI3K/AKT pathway for the treatment of prostate cancer. Clin. Cancer Res. 2009; 15 (15): 4799–4805. Available at: https://pubmed.ncbi.nlm.nih.gov/19638457/ (accessed: April 18, 2021). DOI: 10.1158/1078-0432.CCR-08-0125.

  20. Min Ni, Yiwen Chen, Elgene Lim, Hallie Wimberly, Shannon T. Bailey, Yuuki Imai, David L. Rimm, X. Shirley Liu, Myles Brown. Targeting androgen receptor in estrogen receptor-negative breast cancer. Cancer Cell. 2011; 20 (1): 119–131. Available at: https://pubmed.ncbi.nlm.nih.gov/21741601/ (accessed: April 18, 2021). DOI: 10.1016/j.ccr.2011.05.026.

  21. Francisco E. Vera-Badillo, Arnoud J. Templeton, Paulo de Gouveia, Ivan Diaz-Padilla, Philippe L. Bedard, Mustafa Al-Mubarak, Bostjan Seruga, Ian F. Tannock, Alberto Ocana, Eitan Amir. Androgen receptor expression and outcomes in early breast cancer: a systematic review and meta-analysis. Natl. Cancer Inst. 2014; 106 (1): djt319. Available at: https://pubmed.ncbi.nlm.nih.gov/24273215/ (accessed: April 18, 2021). DOI: 10.1093/jnci/djt319.

  22. Debora Basile, Marika Cinausero, Donatella Iacono, Giacomo Pelizzari, Marta Bonotto, Maria Grazia Vitale, Lorenzo Gerratana, Fabio Puglisi. Androgen receptor in estrogen receptor positive breast cancer: Beyond expression. Cancer Treat. Rev. 2017; 61: 15–22. Available at: https://pubmed.ncbi.nlm.nih.gov/29078133/ (accessed: April 18, 2021). DOI: 10.1016/j.ctrv.2017.09.006.

  23. Ki-Tae Hwang, Young A. Kim, Jongjin Kim, Jeong Hwan Park, In Sil Choi, Kyu Ri Hwang, Young Jun Chai, Jin Hyun Park. Influence of Androgen Receptor on the Prognosis of Breast Cancer. J. Clin. Med. 2020; 9 (4): 1083. Available at: https://pubmed.ncbi.nlm.nih.gov/32290220/ (accessed: April 18, 2021). DOI: 10.3390/jcm9041083.

  24. Kevin H. Kensler, Elizabeth M. Poole, Yujing J. Heng, Laura C. Collins, Benjamin Glass, Andrew H. Beck, Aditi Hazra, Bernard A. Rosner, A. Heather Eliassen, Susan E. Hankinson, Eric P. Winer, Myles Brown, Rulla M. Tamimi. Androgen Receptor Expression and Breast Cancer Survival: Results From the Nurses' Health Studies. J. Natl. Cancer Inst. 2019; 111 (7): 700–708. Available at: https://pubmed.ncbi.nlm.nih.gov/30445651/ (accessed: April 18, 2021). DOI: 10.1093/jnci/djy173.

  25. Barbara Tagliaferri, Erica Quaquarini, Raffaella Palumbo, Emanuela Balletti, Daniele Presti, Alberto Malovini, Manuela Agozzino, Cristina Maria Teragni, Andrea Terzoni, Antonio Bernardo, Laura Villani, Federico Sottotetti. Role of androgen receptor expression in early stage ER+/PgR-/HER2-breast cancer. Ther. Adv. Med. Oncol. 2020; 12: 1758835920958355. Available at: https://pubmed.ncbi.nlm.nih.gov/32994808/ (accessed: April 18, 2021). DOI: 10.1177/1758835920958355.

  26. McNamara K.M., Yoda T., Takagi K., Miki Y., Suzuki T., Sasano H. Androgen receptor in triple negative breast cancer. J. Steroid Biochem. Mol. Biol. 2013; 133: 66–76. Available at: https://pubmed.ncbi.nlm.nih.gov/22982153/ (accessed: April 19, 2021). DOI: 10.1016/j.jsbmb.2012.08.007.

  27. Kristine Astvatsaturyan, Yong Yue, Ann E. Walts, Shikha Bose. Androgen receptor positive triple negative breast cancer: Clinicopathologic, prognostic, and predictive features. PLoS One. 2018; 13 (6): e0197827. Available at: https://pubmed.ncbi.nlm.nih.gov/29883487/ (accessed: April 18, 2021). DOI: 10.1371/journal.pone.0197827.

  28. Teoh P.Y., Tan G.C., Mahsin H., Wong Y.P. Androgen receptor expression in triple negative breast carcinoma and its association with the clinicopathological parameters. Malays J. Pathol. 2019; 41 (2): 125–132. Available at: https://pubmed.ncbi.nlm.nih.gov/31427547/ (accessed: April 19, 2021). PMID: 31427547.

  29. Thomas Grellety. Androgen receptor-positive triple negative breast cancer: From biology to therapy. Bull. Cancer. 2020; 107 (4): 506–516. Available at: https://pubmed.ncbi.nlm.nih.gov/32145961/ (accessed: April 19, 2021). DOI: 10.1016/j.bulcan.2019.12.012.

  30. Xiao-Qing Hu, Wei-Li Chen, Hai-Guang Ma, Ke Jiang. Androgen receptor expression identifies patient with favorable outcome in operable triple negative breast cancer. Oncotarget. 2017; 8 (34): 56364–56374. Available at: https://pubmed.ncbi.nlm.nih.gov/28915596/ (accessed: April 19, 2021). DOI: 10.18632/oncotarget.16913.

  31. Yoshinari Ogawa, Eishu Hai, Kanako Matsumoto, Katsumi Ikeda, Shinya Tokunaga, Hisashi Nagahara, Katsunobu Sakurai, Takeshi Inoue, Yukio Nishiguchi. Androgen receptor expression in breast cancer: relationship with clinicopathological factors and biomarkers. Int. J. Clin. Oncol. 2008; 13 (5): 431–435. Available at: https://pubmed.ncbi.nlm.nih.gov/18946753/ (accessed: April 19, 2021). DOI: 10.1007/s10147-008-0770-6.

  32. Yuka Asano, Shinichiro Kashiwagi, Wataru Goto, Sayaka Tanaka, Tamami Morisaki, Tsutomu Takashima, Satoru Noda, Naoyoshi Onoda, Masahiko Ohsawa, Kosei Hirakawa, Masaichi Ohira. Expression and Clinical Significance of Androgen Receptor in Triple-Negative Breast Cancer Cancers. Cancers (Basel). 2017; 9 (1): 4. Available at: https://www.ncbi.nlm.nih.gov/pubmed/28067809 (accessed: February 11, 2020). DOI: 10.3390/cancers9010004.

  33. Changjun Wang, Bo Pan, Hanjiang Zhu, Yidong Zhou, Feng Mao, Yan Lin, Qianqian Xu, Qiang Sun. Prognostic value of androgen receptor in triple negative breast cancer: A metaanalysis. Oncotarget. 2016; 7 (29): 46482–46491. Available at: https://www.ncbi.nlm.nih.gov/pubmed/27374089 (accessed: February 03, 2020). DOI:10.18632/oncotarget.10208.

  34. Jung Eun Choi, Su Hwan Kang, Soo Jung Lee, Young Kyung Bae. Androgen receptor expression predicts decreased survival in early stage triple-negative breast cancer. Ann. Surg. Oncol. 2015; 22 (1): 82–89. Available at: https://pubmed.ncbi.nlm.nih.gov/25145503/ (accessed: May 19, 2021). DOI: 10.1245/s10434-014-3984-z.

  35. Ivana Mrklić, Zenon Pogorelić, Vesna Capkun, Snjenzana Tomić. Expression of androgen receptors in triple negative breast carcinomas. Acta Histochem. 2013; 115 (4): 344–348. Available at: https://www.ncbi.nlm.nih.gov/pubmed/23031358 (accessed: February 11, 2020). DOI: 10.1016/j.acthis.2012.09.006.

  36. Yan Shen, Fang Yang, Wenwen Zhang, Wei Song, Yuxiu Liu, Xiaoxiang Guan. The Androgen Receptor Promotes Cellular Proliferation by Suppression of G-Protein Coupled Estrogen Receptor Signaling in Triple-Negative Breast Cancer. Cell Physiol. Biochem. 2017; 43 (5): 2047–2061. Available at: https://www.ncbi.nlm.nih.gov/pubmed/29059676 (accessed: February 03, 2020). DOI: 10.1159/000484187.

  37. Ayca Gucalp, Sara Tolaney, Steven J. Isakoff, James N. Ingle, Minetta C. Liu, Lisa A. Carey, Kimberly Blackwell, Hope Rugo, Lisle Nabell, Andres Forero, Vered Stearns, Ashley S. Doane, Michael Danso, Mary Ellen Moynahan, Lamia F. Momen, Joseph M. Gonzalez, Arooj Akhtar, Dilip D. Giri, Sujata Patil, Kimberly N. Feigin, Clifford A. Hudis, Tiffany A. Traina. Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast Cancer. Clin. Cancer Res. 2013; 19 (19): 5505–5512. Available at: https://pubmed.ncbi.nlm.nih.gov/23965901/ (accessed: April 19, 2021). DOI: 10.1158/1078-0432.CCR-12-3327.

  38. Aristomenis Anestis, Ilianna Zoi, Athanasios G Papavassiliou, Michalis V. Karamouzis. Androgen Receptor in Breast Cancer-Clinical and Preclinical Research Insights. Molecules. 2020; 25 (2): 358. Available at: https://pubmed.ncbi.nlm.nih.gov/31952272/ (accessed: April 19, 2021). DOI: 10.3390/molecules25020358.

  39. Bonnefoi H., Grellety T., Tredan O., Saghatchian M., Dalenc F., Mailliez A., L'Haridon T., Cottu P., Abadie-Lacourtoisie S., You B., Mousseau M., Dauba J., Del Piano F., Desmoulins I., Coussy F., Madranges N., Grenier J., Bidard F.C., Proudhon C., MacGrogan G., Orsini C., Pulido M., Gonçalves A. A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1). Ann. Oncol. 2016; 27 (5): 812–818. Available at: https://pubmed.ncbi.nlm.nih.gov/27052658/ (accessed: April 19, 2021). DOI: 10.1093/annonc/mdw067.

  40. Tiffany A. Traina, Kathy Miller, Denise A. Yardley, Janice Eakle, Lee S. Schwartzberg, Joyce O’Shaughnessy, William Gradishar, Peter Schmid, Eric Winer, Catherine Kelly, Rita Nanda, Ayca Gucalp, Ahmad Awada, Laura Garcia-Estevez, Maureen E. Trudeau, Joyce Steinberg, Hirdesh Uppal, Iulia Cristina Tudor, Amy Peterson, Javier Cortes. Enzalutamide for the Treatment of Androgen Receptor-Expressing Triple-Negative Breast Cancer. J. Clin. Oncol. 2018; 36 (9): 884–890. Available at: https://ascopubs.org/doi/full/10.1200/JCO.2016.71.3495?url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub%3Dpubmed&utm_medium=cpc&utm_campaign=J_Clin_Oncol_TrendMD_0&utm_source=TrendMD (accessed: April 19, 2021). DOI:10.1200/JCO.2016.71.3495.

  41. Ayca Gucalp, Tiffany A. Traina. Targeting the androgen receptor in triple-negative breast cancer. Curr. Probl. Cancer. 2016; 40 (2-4): 141–150. Available at: https://pubmed.ncbi.nlm.nih.gov/27816190/ (accessed: April 19, 2021). DOI: 10.1016/j.currproblcancer.2016.09.004.

  42. Jack J. Chan, Tira J.Y. Tan, Rebecca A. Dent. Novel therapeutic avenues in triple-negative breast cancer: PI3K/AKT inhibition, androgen receptor blockade, and beyond. Ther. Adv. Med. Oncol. 2019; 11: 1758835919880429. Available at: https://pubmed.ncbi.nlm.nih.gov/31636720/ (accessed: April 19, 2021). DOI: 10.1177/1758835919880429.

  43. Chun-Yu Liu, Ka-Yi Lau, Chia-Chi Hsu, Ji-Lin Chen, Chia-Han Lee, Tzu-Ting Huang, Yi-Ting Chen, Chun-Teng Huang, Po-Han Lin, Ling-Ming Tseng. Combination of palbociclib with enzalutamide shows in vitro activity in RB proficient and androgen receptor positive triple negative breast cancer cells. PLoS One. 2017; 12 (12): e0189007. Available at: https://pubmed.ncbi.nlm.nih.gov/29261702/ (accessed: April 19, 2021). DOI: 10.1371/journal.pone.0189007.

  44. Carsten Denkert, Cornelia Liedtke, Andrew Tutt, Gunter von Minckwitz. Molecular alterations in triple-negative breast cancer-the road to new treatment strategies. Lancet. 2017; 389 (10087): 2430–2442. Available at: https://pubmed.ncbi.nlm.nih.gov/27939063/ (accessed: April 19, 2021). DOI: 10.1016/S0140-6736(16)32454-0.

  45. Gagan K. Gupta, Amber L. Collier, Dasom Lee, Richard A. Hoefer, Vasilena Zheleva, Lauren L. Siewertsz van Reesema, Angela M. Tang-Tan, Mary L. Guye, David Z. Chang, Janet S. Winston, Billur Samli, Rick J. Jansen, Emanuel F. Petricoin, Matthew P. Goetz, Harry D. Bear, Amy H. Tang. Perspectives on Triple-Negative Breast Cancer: Current Treatment Strategies, Unmet Needs, and Potential Targets for Future Therapies. Cancers (Basel). 2020; 12 (9): 2392. Available at: https://pubmed.ncbi.nlm.nih.gov/32846967/ (accessed: April 19, 2021). DOI: 10.3390/cancers12092392.

  46. Giampaolo Bianchini, Justin M. Balko, Ingrid A. Mayer, Melinda E. Sanders, Luca Gianni. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat. Rev. Clin. Oncol. 2016; 13 (11): 674–690. Available at: https://pubmed.ncbi.nlm.nih.gov/27184417/ (accessed: April 25, 2021). DOI: 10.1038/nrclinonc.2016.66.

  47. Renata Dalmaschio Daltoé, Klesia Pirola Madeira, Alex Assis de Carvalho, Lucas Cunha Dias de Re-zende, Ian Victor Silva, Leticia Batista Azevedo Rangel. Evaluation of the progesterone receptor status in breast cancer using three different antibodies: a comparison by Allred score system. Int. J. Clin. Exp. Pathol. 2013; 7 (1): 331–339. Available at: https://pubmed.ncbi.nlm.nih.gov/24427354/ (accessed: April 25, 2021). PMID: 24427354; PMCID: PMC3885488.

  48. Blamey R.W., Ellis I.O., Pinder S.E., Lee A.H.S., Macmillan R.D., Morgan D.A.L., Robertson J.F.R., Mitchell M.J., Ball G.R., Haybittle J.L., Elston C.W. Survival of invasive breast cancer according to the Nottingham Prognostic Index in cases diagnosed in 1990–1999. Eur. J. Cancer. 2007; 43 (10): 1548–1555. Available at: https://pubmed.ncbi.nlm.nih.gov/17321736/ (accessed: April 25, 2021). DOI: 10.1016/j.ejca.2007.01.016.

  49. Kometova V.V., Zankin V.V., Khayrullin R.M., Rodionov V.V. Patent RF № 2547561; 2013 (in Russian).

  50. Kit O.I., Shatova Yu.S., Tokmakov V.V. Uroven' ekspressii androgenov v opukholevoy tkani i ego prognosticheskoe znachenie pri lyuminal'nom pervichno-operabel'nom rake molochnoy zhelezy bez giperekspressii Her2/neu u zhenshchin v postmenopauze [Androgen expression rate in tumor tissue and its prognostic value in primary operable luminal breast cancer without Her2/neu overexpression in postmenopausal women]. Kazanskiy meditsinskiy zhurnal. 2019; 1. Available at: https://cyberleninka.ru/article/n/uroven-ekspressii-retseptorov-androgenov-v-opuholevoy-tkani-i-ego-prognosticheskoe-znachenie-pri-lyuminalnom-pervichno-operabelnom/ (accessed: April 04, 2021). DOI: 10.17816/KMJ2019-112.

Received 15 March 2021; accepted 24 May 2021.

 

Information about the authors

Panchenko Ivan Sergeevich, Post-graduate Student, Chair of Oncology and Radiation Diagnostics, Medical Department named after T.Z. Biktimirov, Ulyanovsk State University. 432017, Russia, Ulyanovsk, L. Tolstoy St., 42; e-mail: Этот адрес электронной почты защищён от спам-ботов. У вас должен быть включен JavaScript для просмотра., ORCID ID: http://orcid.org/0000-0001-7923-4317

Rodionov Valeriy Vital'evich, Doctor of Sciences (Medicine), Head of the Department of Breast Pathology, National Medical Research Center for Obstetrics, Gynecology and Perinatology named after V.I. Kulakov, Ministry of Health of the Russian Federation. 117997, Russia, Moscow, Akademik Oparin St., 4; e-mail: Этот адрес электронной почты защищён от спам-ботов. У вас должен быть включен JavaScript для просмотра., ORCID ID: http://orcid.org/0000-0003-0096-7126

Panchenko Sergey Viktorovich, Candidate of Sciences (Medicine), Associate Professor, Chair of Oncology and Radiation Diagnostics, Medical Department named after T.Z. Biktimirov, Ulyanovsk State University. 432017, Russia, Ulyanovsk, L. Tolstoy St., 42; e-mail: Этот адрес электронной почты защищён от спам-ботов. У вас должен быть включен JavaScript для просмотра., ORCID: http://orcid.org/0000-0002-9006-2023

Sharafutdinov Marat Gakifovich, Candidate of Sciences (Medicine), Head of the Chair of Oncology and Radiation Diagnostics, Medical Department named after T.Z. Biktimirov, Ulyanovsk State University. 432017, Russia, Ulyanovsk, L. Tolstoy St., 42; e-mail: Этот адрес электронной почты защищён от спам-ботов. У вас должен быть включен JavaScript для просмотра.; ORCID: http://orcid.org/0000-0002-8782-4111

 

For citation

Panchenko I.S., Rodionov V.V., Panchenko S.V., Sharafutdinov M.G. Osobennosti kliniki, prognoza i lecheniya androgen-retseptor-pozitivnogo trizhdy negativnogo raka molochnoy zhelezy [Clinical features, prognosis and treatment of androgen-receptor-positive triple-negative breast cancer]. Ul'yanovskiy mediko-biologicheskiy zhurnal. 2021; 2: 83–96. DOI: 10.34014/2227-1848-2021-2-83-96 (in Russian).

 

Скачать статью

УДК 616-006.699

DOI 10.34014/2227-1848-2021-2-83-96

ОСОБЕННОСТИ КЛИНИКИ, ПРОГНОЗА И ЛЕЧЕНИЯ АНДРОГЕН-РЕЦЕПТОР-ПОЗИТИВНОГО ТРИЖДЫ НЕГАТИВНОГО РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ

И.С. Панченко1, В.В. Родионов2, С.В. Панченко1, М.Г. Шарафутдинов1

1 ФГБОУ ВО «Ульяновский государственный университет», г. Ульяновск, Россия;

2 ФГБУ «Национальный медицинский исследовательский центр акушерства, гинекологии и перинатологии им. академика В.И. Кулакова» Министерства здравоохранения РФ, г. Москва, Россия

 

Данный литературный обзор посвящен рассмотрению прогностических, клинических и лечебных особенностей андроген-рецептор-позитивного трижды негативного рака молочной железы.

Рак молочной железы (РМЖ) – самая распространенная злокачественная опухоль среди женского населения, на ее долю приходится около 21 % всех случаев злокачественных новообразований в Российской Федерации. Наиболее неблагоприятным подтипом РМЖ является трижды негативный рак молочной железы (ТНРМЖ). ТНРМЖ – это подгруппа злокачественных опухолей молочной железы, характеризующихся агрессивным течением и неблагоприятным прогнозом, наиболее часто поражающих женщин молодого возраста. Несмотря на высокую чувствительность к неоадъювантной полиохимиотерапии, частота локорегионарного рецидива при ТНРМЖ остается высокой. Выживаемость при ТНРМЖ по сравнению с другими подтипами РМЖ ниже. Благодаря широкому внедрению молекулярно-генетических методов исследования в алгоритмы диагностики РМЖ можно утверждать, что ТНРМЖ – это гетерогенная группа опухолей с различным прогнозом, клиническими особенностями и ответом на лечение. В настоящее время лекарственная терапия ТНРМЖ опирается исключительно на системную химиотерапию, каких-либо мишеней для лечения этого вида опухолей в национальных стандартах не существует. Однако, согласно последним исследованиям, в терапии ТНРМЖ с успехом могут быть применены антиандрогенные препараты. Представляется перспективным изучение андроген-рецептор-позитивного трижды негативного рака молочной железы по двум причинам. Первая – возможность ИГХ-диагностики в большинстве онкологических центров РФ, вторая – возможность использования доступного и относительно недорого вида лечения – эндокринной терапии.

Ключевые слова: рак молочной железы, трижды негативный рак молочной железы, андроген-рецептор-позитивный трижды негативный рак молочной железы, андрогенные рецепторы, экспрессия андрогенных рецепторов, антиандрогенная терапия.

 

Литература

  1. Чиссов В.И., Дарьялова С.Л. Онкология: учебник с компакт-диском. М.: ГЭОТАР-Медиа; 2009. 560.

  2. GLOBOCAN 2020. URL: https://acsjournals.onlinelibrary.wiley.com/doi/full/10.3322/caac.21660 (дата обращения: 27.04.2021).

  3. Каприн А.Д., Старинский В.В., Шахзадова А.О. Злокачественные новообразования в России в 2019 году. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России; 2020. 252.

  4. Pankaj Kumar, Rupali Aggarwal. An overview of triple-negative breast cancer. Arch. Gynecol. Obstet. 2016; 293 (2): 247–269. URL: https://pubmed.ncbi.nlm.nih.gov/26341644/ (дата обращения: 16.04.2021). DOI: 10.1007/s00404-015-3859-y.

  5. Lubna N. Chaudhary. Early stage triple negative breast cancer: Management and future directions. Semin. Oncol. 2020; 47 (4): 201–208. URL: https://pubmed.ncbi.nlm.nih.gov/32507668/ (дата обращения: 16.04.2021). DOI: 10.1053/j.seminoncol.2020.05.006.

  6. Cornelia Liedtke, Chafika Mazouni, Kenneth R. Hess, Fabrice André, Attila Tordai, Jaime A. Mejia, W. Fraser Symmans, Ana M. Gonzalez-Angulo, Bryan Hennessy, Marjorie Green, Massimo Cristofanilli, Gabriel N. Hortobagyi, Lajos Pusztai. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J. Clin. Oncol. 2008; 26 (8): 1275–1281. URL: https://pubmed.ncbi.nlm.nih.gov/18250347/ (дата обращения: 16.04.2021). DOI: 10.1200/JCO.2007.14.4147.

  7. Xiaoxian Li, Jing Yang, Limin Peng, Aysegul A. Sahin, Lei Huo, Kevin C. Ward, Ruth O'Regan, Mylin A. Torres, Jane L. Meisel. Triple-negative breast cancer has worse overall survival and cause-specific survival than non-triple-negative breast cancer. Breast Cancer Res. Treat. 2017; 161 (2): 279–287. URL: https://pubmed.ncbi.nlm.nih.gov/27888421/ (дата обращения: 16.04.2021). DOI: 10.1007/s10549-016-4059-6.

  8. Marissa C. van Maaren, Linda de Munck, Luc J.A. Strobbe, Gabe S. Sonke, Pieter J. Westenend, Marjolein L. Smidt, Philip M.P. Poortmans, Sabine Siesling. Ten-year recurrence rates for breast cancer subtypes in the Netherlands: A large population-based study. Int. J. Cancer. 2019; 144 (2): 263–272. URL: https://pubmed.ncbi.nlm.nih.gov/30368776/ (дата обращения: 17.04.2021). DOI: 10.1002/ijc.31914.

  9. Zuzana Sporikova, Vladimira Koudelakova, Radek Trojanec, Marian Hajduch. Genetic Markers in Triple-Negative Breast Cancer. Clin. Breast Cancer. 2018; 18 (5): e841–e850. URL: https://pubmed.ncbi.nlm.nih.gov/30146351/ (дата обращения: 16.04.2021). DOI: 10.1016/j.clbc.2018.07.023.

  10. Perou C.M., Sørlie T., Eisen M.B., van de Rijn M., Jeffrey S.S., Rees C.A., Pollack J.R., Ross D.T., Johnsen H., Akslen L.A., Fluge O., Pergamenschikov A., Williams C., Zhu S.X., Lønning P.E., Børresen-Dale A.L., Brown P.O., Botstein D. Molecular portraits of human breast tumours. Nature. 2000; 406 (6797): 747–752. URL: https://pubmed.ncbi.nlm.nih.gov/10963602/ (дата обращения: 17.04.2021). DOI: 10.1038/35021093.

  11. Aleix Prat, Joel S. Parker, Olga Karginova, Cheng Fan, Chad Livasy, Jason I. Herschkowitz, Xiaping He, Charles M. Perou. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res. 2010; 12 (5): R68. URL: https://pubmed.ncbi.nlm.nih.gov/20813035/ (дата обращения: 17.04.2021). DOI: 10.1186/bcr2635.

  12. Farmer Pierre, Bonnefoi Herve, Becette Veronique, Tubiana-Hulin Michele, Fumoleau Pierre, Larsimont Denis, Macgrogan Gaetan, Bergh Jonas, Cameron David, Goldstein Darlene, Duss Stephan, Nicoulaz Anne-Laure, Brisken Cathrin, Fiche Maryse, Delorenzi Mauro, Iggo Richard. Identification of molecular apocrine breast tumours by microarray analysis. Oncogene. 2005; 24 (29): 4660–4671. URL: https://pubmed.ncbi.nlm.nih.gov/15897907/ (дата обращения: 17.04.2021). DOI: 10.1038/sj.onc.1208561.

  13. Fitzal F., Filipits M., Fesl C., Rudas M., Greil R., Balic M., Moinfar F., Herz W., Dubsky P., Bartsch R., Ferree S., Schaper C., Gnant M. PAM-50 predicts local recurrence after breast cancer surgery in postmenopausal patients with ER+/HER2- disease: results from 1204 patients in the randomized ABCSG-8 trial. Br. J. Surg. 2021; 108 (3): 308–314. URL: https://pubmed.ncbi.nlm.nih.gov/33608712/ (дата обращения: 17.04.2021). DOI: 10.1093/bjs/znaa089.

  14. Brian D. Lehmann, Joshua A. Bauer, Xi Chen, Melinda E. Sanders, A. Bapsi Chakravarthy, Yu Shyr, Jennifer A. Pietenpol. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J. Clin. Invest. 2011; 121 (7): 2750–2767. URL: https://pubmed.ncbi.nlm.nih.gov/21633166/ (дата обращения: 18.04.2021). DOI: 10.1172/JCI45014.

  15. Li Yin, Jiang-Jie Duan, Xiu-Wu Bian, Shi-Cang Yu. Triple-negative breast cancer molecular subtyping and treatment progress. Breast Cancer Res. 2020; 22 (1): 61. URL: https://pubmed.ncbi.nlm.nih.gov/32517735/ (дата обращения: 18.04.2021). DOI: 10.1186/s13058-020-01296-5.

  16. Matthew D. Burstein, Anna Tsimelzon, Graham M. Poage, Kyle R. Covington, Alejandro Contreras, Suzanne A.W. Fuqua, Michelle I. Savage, C. Kent Osborne , Susan G. Hilsenbeck, Jenny C. Chang, Gordon B. Mills, Ching C. Lau, Powel H. Brown. Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer. Clin. Cancer Res. 2015; 21 (7): 1688–1698. URL: https://pubmed.ncbi.nlm.nih.gov/25208879/ (дата обращения: 18.04.2021). DOI: 10.1158/1078-0432.CCR-14-0432.

  17. Yi-Rong Liu, Yi-Zhou Jiang, Xiao-En Xu, Ke-Da Yu, Xi Jin, Xin Hu, Wen-Jia Zuo, Shuang Hao, Jiong Wu, Guang-Yu Liu, Gen-Hong Di, Da-Qiang Li, Xiang-Huo He, Wei-Guo Hu, Zhi-Ming Shao. Comprehensive transcriptome analysis identifies novel molecular subtypes and subtype-specific RNAs of triple-negative breast cancer. Breast Cancer Res. 2016; 18 (1): 33. URL: https://pubmed.ncbi.nlm.nih.gov/26975198/ (дата обращения: 18.04.2021). DOI: 10.1186/s13058-016-0690-8.

  18. Clasina M. Venema, Rico D. Bense, Tessa G. Steenbruggen, Hilde H. Nienhuis, Si-Qi Qiu, Michel van Kruchten, Myles Brown, Rulla M. Tamimi, Geke A.P. Hospers, Carolina P. Schröder, Rudolf S.N. Fehrmann, Elisabeth G.E. de Vries. Consideration of breast cancer subtype in targeting the androgen receptor. Pharmacol. Ther. 2019; 200: 135–147 URL: https://pubmed.ncbi.nlm.nih.gov/31077689/ (дата обращения: 18.04.2021). DOI: 10.1016/j.pharmthera.2019.05.005.

  19. Debashis Sarker, Alison H.M. Reid, Timothy A. Yap, Johann S. de Bono. Targeting the PI3K/AKT pathway for the treatment of prostate cancer. Clin. Cancer Res. 2009; 15 (15): 4799–4805. URL: https://pubmed.ncbi.nlm.nih.gov/19638457/ (дата обращения: 18.04.2021). DOI: 10.1158/1078-0432.CCR-08-0125.

  20. Min Ni, Yiwen Chen, Elgene Lim, Hallie Wimberly, Shannon T. Bailey, Yuuki Imai, David L. Rimm, X. Shirley Liu, Myles Brown. Targeting androgen receptor in estrogen receptor-negative breast cancer. Cancer Cell. 2011; 20 (1): 119–131. URL: https://pubmed.ncbi.nlm.nih.gov/21741601/ (дата обращения: 18.04.2021). DOI: 10.1016/j.ccr.2011.05.026.

  21. Francisco E. Vera-Badillo, Arnoud J. Templeton, Paulo de Gouveia, Ivan Diaz-Padilla, Philippe L. Bedard, Mustafa Al-Mubarak, Bostjan Seruga, Ian F. Tannock, Alberto Ocana, Eitan Amir. Androgen receptor expression and outcomes in early breast cancer: a systematic review and meta-analysis. Natl. Cancer Inst. 2014; 106 (1): djt319. URL: https://pubmed.ncbi.nlm.nih.gov/24273215/ (дата обращения: 18.04.2021). DOI: 10.1093/jnci/djt319.

  22. Debora Basile, Marika Cinausero, Donatella Iacono, Giacomo Pelizzari, Marta Bonotto, Maria Grazia Vitale, Lorenzo Gerratana, Fabio Puglisi. Androgen receptor in estrogen receptor positive breast cancer: Beyond expression. Cancer Treat. Rev. 2017; 61: 15–22. URL: https://pubmed.ncbi.nlm.nih.gov/29078133/ (дата обращения: 18.04.2021). DOI: 10.1016/j.ctrv.2017.09.006.

  23. Ki-Tae Hwang, Young A. Kim, Jongjin Kim, Jeong Hwan Park, In Sil Choi, Kyu Ri Hwang, Young Jun Chai, Jin Hyun Park. Influence of Androgen Receptor on the Prognosis of Breast Cancer. J. Clin. Med. 2020; 9 (4): 1083. URL: https://pubmed.ncbi.nlm.nih.gov/32290220/ (дата обращения: 18.04.2021). DOI: 10.3390/jcm9041083.

  24. Kevin H. Kensler, Elizabeth M. Poole, Yujing J. Heng, Laura C. Collins, Benjamin Glass, Andrew H. Beck, Aditi Hazra, Bernard A. Rosner, A. Heather Eliassen, Susan E. Hankinson, Eric P. Winer, Myles Brown, Rulla M. Tamimi. Androgen Receptor Expression and Breast Cancer Survival: Results From the Nurses' Health Studies. J. Natl. Cancer Inst. 2019; 111 (7): 700–708. URL: https://pubmed.ncbi.nlm.nih.gov/30445651/ (дата обращения: 18.04.2021). DOI: 10.1093/jnci/djy173.

  25. Barbara Tagliaferri, Erica Quaquarini, Raffaella Palumbo, Emanuela Balletti, Daniele Presti, Alberto Malovini, Manuela Agozzino, Cristina Maria Teragni, Andrea Terzoni, Antonio Bernardo, Laura Villani, Federico Sottotetti. Role of androgen receptor expression in early stage ER+/PgR-/HER2-breast cancer. Ther. Adv. Med. Oncol. 2020; 12: 1758835920958355. URL: https://pubmed.ncbi.nlm.nih.gov/32994808/ (дата обращения: 18.04.2021). DOI: 10.1177/1758835920958355.

  26. McNamara K.M., Yoda T., Takagi K., Miki Y., Suzuki T., Sasano H. Androgen receptor in triple negative breast cancer. J. Steroid Biochem Mol. Biol. 2013; 133: 66–76. URL: https://pubmed.ncbi.nlm.nih.gov/22982153/ (дата обращения: 19.04.2021). DOI: 10.1016/j.jsbmb.2012.08.007.

  27. Kristine Astvatsaturyan, Yong Yue, Ann E. Walts, Shikha Bose. Androgen receptor positive triple negative breast cancer: Clinicopathologic, prognostic, and predictive features. PLoS One. 2018; 13 (6): e0197827. URL: https://pubmed.ncbi.nlm.nih.gov/29883487/ (дата обращения: 18.04.2021). DOI: 10.1371/journal.pone.0197827.

  28. Teoh P.Y., Tan G.C., Mahsin H., Wong Y.P. Androgen receptor expression in triple negative breast carcinoma and its association with the clinicopathological parameters. Malays J. Pathol. 2019; 41 (2): 125–132. URL: https://pubmed.ncbi.nlm.nih.gov/31427547/ (дата обращения: 19.04.2021). PMID: 31427547.

  29. Thomas Grellety. Androgen receptor-positive triple negative breast cancer: From biology to therapy. Bull. Cancer. 2020; 107 (4): 506–516. URL: https://pubmed.ncbi.nlm.nih.gov/32145961/ (дата обращения: 19.04.2021). DOI: 10.1016/j.bulcan.2019.12.012.

  30. Xiao-Qing Hu, Wei-Li Chen, Hai-Guang Ma, Ke Jiang. Androgen receptor expression identifies patient with favorable outcome in operable triple negative breast cancer. Oncotarget. 2017; 8 (34): 56364–56374. URL: https://pubmed.ncbi.nlm.nih.gov/28915596/ (дата обращения: 19.05.2021). DOI: 10.18632/oncotarget.16913.

  31. Yoshinari Ogawa, Eishu Hai, Kanako Matsumoto, Katsumi Ikeda, Shinya Tokunaga, Hisashi Nagahara, Katsunobu Sakurai, Takeshi Inoue, Yukio Nishiguchi. Androgen receptor expression in breast cancer: relationship with clinicopathological factors and biomarkers. Int. J. Clin. Oncol. 2008; 13 (5): 431–435. URL: https://pubmed.ncbi.nlm.nih.gov/18946753/ (дата обращения: 19.05.2021). DOI: 10.1007/s10147-008-0770-6.

  32. Yuka Asano, Shinichiro Kashiwagi, Wataru Goto, Sayaka Tanaka, Tamami Morisaki, Tsutomu Takashima, Satoru Noda, Naoyoshi Onoda, Masahiko Ohsawa, Kosei Hirakawa, Masaichi Ohira. Expression and Clinical Significance of Androgen Receptor in Triple-Negative Breast Cancer Cancers. Cancers (Basel). 2017; 9 (1): 4. URL: https://www.ncbi.nlm.nih.gov/pubmed/28067809 (дата обращения: 11.02.2020). DOI: 10.3390/cancers9010004.

  33. Changjun Wang, Bo Pan, Hanjiang Zhu, Yidong Zhou, Feng Mao, Yan Lin, Qianqian Xu, Qiang Sun. Prognostic value of androgen receptor in triple negative breast cancer: A metaanalysis. Oncotarget. 2016; 7 (29): 46482–46491. URL: https://www.ncbi.nlm.nih.gov/pubmed/27374089 (дата обращения 03.02.2020). DOI:10.18632/oncotarget.10208.

  34. Jung Eun Choi, Su Hwan Kang, Soo Jung Lee, Young Kyung Bae. Androgen receptor expression predicts decreased survival in early stage triple-negative breast cancer. Ann. Surg. Oncol. 2015; 22 (1): 82–89. URL: https://pubmed.ncbi.nlm.nih.gov/25145503/ (дата обращения: 19.05.2021). DOI: 10.1245/s10434-014-3984-z.

  35. Ivana Mrklić, Zenon Pogorelić, Vesna Capkun, Snjenzana Tomić. Expression of androgen receptors in triple negative breast carcinomas. Acta Histochem. 2013; 115 (4): 344–348. URL: https://www.ncbi.nlm.nih.gov/pubmed/23031358 (дата обращения: 11.02.2020). DOI: 10.1016/j.acthis.2012.09.006.

  36. Yan Shen, Fang Yang, Wenwen Zhang, Wei Song, Yuxiu Liu, Xiaoxiang Guan. The Androgen Receptor Promotes Cellular Proliferation by Suppression of G-Protein Coupled Estrogen Receptor Signaling in Triple-Negative Breast Cancer. Cell Physiol. Biochem. 2017; 43 (5): 2047–2061. URL: https://www.ncbi.nlm.nih.gov/pubmed/29059676 (дата обращения: 03.02.2020). DOI: 10.1159/000484187.

  37. Ayca Gucalp, Sara Tolaney, Steven J. Isakoff, James N. Ingle, Minetta C. Liu, Lisa A. Carey, Kimberly Blackwell, Hope Rugo, Lisle Nabell, Andres Forero, Vered Stearns, Ashley S. Doane, Michael Danso, Mary Ellen Moynahan, Lamia F. Momen, Joseph M. Gonzalez, Arooj Akhtar, Dilip D. Giri, Sujata Patil, Kimberly N. Feigin, Clifford A. Hudis, Tiffany A. Traina. Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast Cancer. Clin. Cancer Res. 2013; 19 (19): 5505–5512. URL: https://pubmed.ncbi.nlm.nih.gov/23965901/ (дата обращения: 19.04.2021). DOI: 10.1158/1078-0432.CCR-12-3327.

  38. Aristomenis Anestis, Ilianna Zoi, Athanasios G Papavassiliou, Michalis V. Karamouzis. Androgen Receptor in Breast Cancer-Clinical and Preclinical Research Insights. Molecules. 2020; 25 (2): 358. URL: https://pubmed.ncbi.nlm.nih.gov/31952272/ (дата обращения: 19.04.2021). DOI: 10.3390/molecules25020358.

  39. Bonnefoi H., Grellety T., Tredan O., Saghatchian M., Dalenc F., Mailliez A., L'Haridon T., Cottu P., Abadie-Lacourtoisie S., You B., Mousseau M., Dauba J., Del Piano F., Desmoulins I., Coussy F., Madranges N., Grenier J., Bidard F.C., Proudhon C., MacGrogan G., Orsini C., Pulido M., Gonçalves A. A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1). Ann. Oncol. 2016; 27 (5): 812–818. URL: https://pubmed.ncbi.nlm.nih.gov/27052658/ (дата обращения: 19.04.2021). DOI: 10.1093/annonc/mdw067.

  40. Tiffany A. Traina, Kathy Miller, Denise A. Yardley, Janice Eakle, Lee S. Schwartzberg, Joyce O’Shaughnessy, William Gradishar, Peter Schmid, Eric Winer, Catherine Kelly, Rita Nanda, Ayca Gucalp, Ahmad Awada, Laura Garcia-Estevez, Maureen E. Trudeau, Joyce Steinberg, Hirdesh Uppal, Iulia Cristina Tudor, Amy Peterson, Javier Cortes. Enzalutamide for the Treatment of Androgen Receptor-Expressing Triple-Negative Breast Cancer. J. Clin. Oncol. 2018; 36 (9): 884–890. URL: https://ascopubs.org/doi/full/10.1200/JCO.2016.71.3495?url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub%3Dpubmed&utm_medium=cpc&utm_campaign=J_Clin_Oncol_TrendMD_0&utm_source=TrendMD (дата обращения: 19.04.2021). DOI:10.1200/JCO.2016.71.3495.

  41. Ayca Gucalp, Tiffany A. Traina. Targeting the androgen receptor in triple-negative breast cancer. Curr. Probl. Cancer. 2016; 40 (2–4): 141–150. URL: https://pubmed.ncbi.nlm.nih.gov/27816190/ (дата обращения: 19.04.2021). DOI: 10.1016/j.currproblcancer.2016.09.004.

  42. Jack J. Chan, Tira J.Y. Tan, Rebecca A. Dent. Novel therapeutic avenues in triple-negative breast cancer: PI3K/AKT inhibition, androgen receptor blockade, and beyond. Ther. Adv. Med. Oncol. 2019; 11: 1758835919880429. URL: https://pubmed.ncbi.nlm.nih.gov/31636720/ (дата обращения: 19.04.2021). DOI: 10.1177/1758835919880429.

  43. Chun-Yu Liu, Ka-Yi Lau, Chia-Chi Hsu, Ji-Lin Chen, Chia-Han Lee, Tzu-Ting Huang, Yi-Ting Chen, Chun-Teng Huang, Po-Han Lin, Ling-Ming Tseng. Combination of palbociclib with enzalutamide shows in vitro activity in RB proficient and androgen receptor positive triple negative breast cancer cells. PLoS One. 2017; 12 (12): e0189007. URL: https://pubmed.ncbi.nlm.nih.gov/29261702/ (дата обращения: 19.04.2021). DOI: 10.1371/journal.pone.0189007.

  44. Carsten Denkert, Cornelia Liedtke, Andrew Tutt, Gunter von Minckwitz. Molecular alterations in triple-negative breast cancer-the road to new treatment strategies. Lancet. 2017; 389 (10087): 2430–2442. URL: https://pubmed.ncbi.nlm.nih.gov/27939063/ (дата обращения: 19.04.2021). DOI: 10.1016/S0140-6736(16)32454-0.

  45. Gagan K. Gupta, Amber L. Collier, Dasom Lee, Richard A. Hoefer, Vasilena Zheleva, Lauren L. Siewertsz van Reesema, Angela M. Tang-Tan, Mary L. Guye, David Z. Chang, Janet S. Winston, Billur Samli, Rick J. Jansen, Emanuel F. Petricoin, Matthew P. Goetz, Harry D. Bear, Amy H. Tang. Perspectives on Triple-Negative Breast Cancer: Current Treatment Strategies, Unmet Needs, and Potential Targets for Future Therapies. Cancers (Basel). 2020; 12 (9): 2392. URL: https://pubmed.ncbi.nlm.nih.gov/32846967/ (дата обращения: 19.04.2021). DOI: 10.3390/cancers12092392.

  46. Giampaolo Bianchini, Justin M. Balko, Ingrid A. Mayer, Melinda E. Sanders, Luca Gianni. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat. Rev. Clin. Oncol. 2016; 13 (11): 674–690. URL: https://pubmed.ncbi.nlm.nih.gov/27184417/ (дата обращения: 25.04.2021). DOI: 10.1038/nrclinonc.2016.66.

  47. Renata Dalmaschio Daltoé, Klesia Pirola Madeira, Alex Assis de Carvalho, Lucas Cunha Dias de Rezende, Ian Victor Silva, Leticia Batista Azevedo Rangel. Evaluation of the progesterone receptor status in breast cancer using three different antibodies: a comparison by Allred score system. Int. J. Clin. Exp. Pathol. 2013; 7 (1): 331–339. URL: https://pubmed.ncbi.nlm.nih.gov/24427354/ (дата обращения: 25.04.2021). PMID: 24427354; PMCID: PMC3885488.

  48. Blamey R.W., Ellis I.O., Pinder S.E., Lee A.H.S., Macmillan R.D., Morgan D.A.L., Robertson J.F.R., Mitchell M.J., Ball G.R., Haybittle J.L., Elston C.W. Survival of invasive breast cancer according to the Nottingham Prognostic Index in cases diagnosed in 1990–1999. Eur. J. Cancer. 2007; 43 (10): 1548–1555. URL: https://pubmed.ncbi.nlm.nih.gov/17321736/ (дата обращения: 25.04.2021). DOI: 10.1016/j.ejca.2007.01.016.

  49. Кометова В.В., Занкин В.В., Хайруллин Р.М., Родионов В.В. Патент РФ № 2547561; 2013.

  50. Кит О.И., Шатова Ю.С., Токмаков В.В. Уровень экспрессии андрогенов в опухолевой ткани и его прогностическое значение при люминальном первично-операбельном раке молочной железы без гиперэкспрессии Her2/neu у женщин в постменопаузе. Казанский медицинский журнал. 2019; 1. URL: https://cyberleninka.ru/article/n/uroven-ekspressii-retseptorov-androgenov-v-opuholevoy-tkani-i-ego-prognosticheskoe-znachenie-pri-lyuminalnom-pervichno-operabelnom (дата обращения 04.04.2021). DOI: 10.17816/KMJ2019-112.

Поступила в редакцию 15.03.2021; принята 24.05.2021.

 

Авторский коллектив

Панченко Иван Сергеевич – аспирант кафедры онкологии и лучевой диагностики медицинского факультета им. Т.З. Биктимирова, ФГБОУ ВО «Ульяновский государственный университет». 432017, Россия, г. Ульяновск, ул. Л. Толстого, 42; e-mail: Этот адрес электронной почты защищён от спам-ботов. У вас должен быть включен JavaScript для просмотра., ORCID ID: http://orcid.org/0000-0001-7923-4317

Родионов Валерий Витальевич – доктор медицинских наук, заведующий отделением патологии молочной железы, ФГБУ «Национальный медицинский исследовательский центр акушерства, гинекологии и перинатологии им. академика В.И. Кулакова» Министерства здравоохранения РФ. 117997, Россия, г. Москва, ул. Академика Опарина, 4; e-mail: Этот адрес электронной почты защищён от спам-ботов. У вас должен быть включен JavaScript для просмотра., ORCID ID: http://orcid.org/0000-0003-0096-7126

Панченко Сергей Викторович – кандидат медицинских наук, доцент кафедры онкологии и лучевой диагностики медицинского факультета им. Т.З. Биктимирова, ФГБОУ ВО «Ульяновский государственный университет». 432017, Россия, г. Ульяновск, ул. Л. Толстого, 42; e-mail: Этот адрес электронной почты защищён от спам-ботов. У вас должен быть включен JavaScript для просмотра., ORCID: http://orcid.org/0000-0002-9006-2023

Шарафутдинов Марат Гакифович – кандидат медицинских наук, заведующий кафедрой онкологии и лучевой диагностики медицинского факультета им. Т.З. Биктимирова, ФГБОУ ВО «Ульяновский государственный университет». 432017, Россия, г. Ульяновск, ул. Л. Толстого, 42; e-mail: Этот адрес электронной почты защищён от спам-ботов. У вас должен быть включен JavaScript для просмотра.; ORCID: http://orcid.org/0000-0002-8782-4111

 

Образец цитирования

Панченко И.С., Родионов В.В., Панченко С.В., Шарафутдинов М.Г. Особенности клиники, прогноза и лечения андроген-рецептор-позитивного трижды негативного рака молочной железы. Ульяновский медико-биологический журнал. 2021; 2: 83–96. DOI: 10.34014/2227-1848-2021-2-83-96.